BGB-16673: A phase 1 and 2 trial of BGB-16673 in people with B-cell lymphomas

This trial aims to test the medication BGB-16673 in people with B-cell lymphomas.

You can share the following clinicaltrials.gov Identifier with your medical team so they can find out more about the trial: NCT05006716

Trial aim and background

The aim of this trial is to establish the best dose of the treatment BGB-16673 and then to test how safe and effective it is at this dose.

BGB-16673 is a type of targeted treatment called a BTK targeted protein degrader. BTK is part of a pathway that helps B-cells to stay alive and divide. BGB-16673 breaks down BTK which can make B-cells die, or stop them from dividing.

This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future. 

Who can enter 

Adults with one of the following B-cell lymphomas may be eligible for this trial:

  • Marginal zone lymphoma (MZL)
  • Follicular lymphoma (FL)
  • Mantle cell lymphoma (MCL)
  • Chronic lymphocytic leukaemia and small lymphocytic lymphoma (CLL/SLL)
  • Waldenstrom macroglobulinaemia (WM)
  • Diffuse large B-cell lymphoma (DLBCL)

Locations 

Recruitment is taking place at the following UK locations:

  • Churchill Hospital Oxford University Hospital NHS Trust, Headington
  • St James University Hospital, Leeds
  • Freeman Hospital, Newcastle
  • Derriford Hospital, Plymouth
  • Edinburgh Hospitals, Edinburgh

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05006716

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.